BioNTech

US · BNTX #801 by market cap Listed 2019

95.25 -0.48 -0.50%

Live - 5344 symbols - heartbeat 262s ago · 2026-10-08 08:10

Pre-market 94.20 -1.10%

After-hours 96.00 +0.79%

Overnight 95.00 -0.26%

Market cap: 23.93B
P/E (TTM): -12.68
P/B: 1.20
EPS: -5.26
Div yield: 0.00%
52W pos: 35%

Reader sentiment Are you bullish or bearish on BNTX?

Anonymous reader poll. Unscientific, not investment advice.

About BioNTech

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Founded: 2008
CEO: Professor Ugur Sahin, M.D.
Employees: 7,807
Headquarters: Mainz, Rheinland-Pfalz, Germany
Fiscal year end: 12-31
Website: biontech.de

Company profile

Exchange: US
Symbol: BNTX
Market-cap rank: #801
Listing date: 2019-10-10
Market cap: 23.93B
Float cap: 10.39B
Shares out: 251.20M
Float shares: 109.10M

Sectors & themes

Biotechnology Infectious Disease Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 08:10:13 · For reference only, not investment advice and not tailored to your situation.